Glenmark Pharmaceuticals Ltd (GLENMARK):企業の財務・戦略的SWOT分析

◆英語タイトル:Glenmark Pharmaceuticals Ltd (GLENMARK) - Financial and Strategic SWOT Analysis Review
◆商品コード:SWOT20MY0432
◆発行会社(調査会社):GlobalData
◆発行日:2019年12月
◆ページ数:56
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:インド
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥13,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥26,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥39,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Glenmark Pharmaceuticals Ltd (GLENMARK) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Glenmark Pharmaceuticals Ltd (Glenmark) focuses on the discovery of new chemical entities (NCEs) and new biological entities (NBEs). The company’s formulations business encompasses therapeutic areas such as dermatology, anti-infective, respiratory, central nervous system, and oncology. It also offers a wide range of generic products. The company manufactures and supplies active pharmaceutical ingredients (APIs). Glenmark developed a proprietary platform, Bispecific Engagement by antibodies based on the T-cell receptor (BEAT) for production of bispecific antibodies. The company markets its products in North America, South America, Asia-Pacific and Africa. Glenmark is headquartered in Mumbai, Maharashtra, India.

Glenmark Pharmaceuticals Ltd Key Recent Developments

Nov 14,2019: Glenmark’s consolidated revenue rises 9.05% to Rs. 28,150.4 Mn. in Q2 FY 2019-20
Oct 05,2019: Glenmark Pharmaceuticals: Update on the US FDA inspection of Glenmark’s Baddi manufacturing facility in Himachal Pradesh
Oct 03,2019: US FDA issues warning letter to Glenmark Pharmaceuticals
Aug 13,2019: Glenmark’s consolidated revenue atRs.23,228.79 Mn.for Q1 FY 2019–20
May 07,2019: Glenmark appoints Dr. Yasir Rawjee as chief executive officer of Glenmark Life Sciences, its subsidiary for the API business

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Glenmark Pharmaceuticals Ltd – Key Facts
Glenmark Pharmaceuticals Ltd – Key Employees
Glenmark Pharmaceuticals Ltd – Key Employee Biographies
Glenmark Pharmaceuticals Ltd – Major Products and Services
Glenmark Pharmaceuticals Ltd – History
Glenmark Pharmaceuticals Ltd – Company Statement
Glenmark Pharmaceuticals Ltd – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Glenmark Pharmaceuticals Ltd – Business Description
Product Category: Other Operating Revenue
Performance
Product Category: Sale of Products
Performance
Product Category: Sale of Services
Performance
Geographical Segment: Europe
Performance
Geographical Segment: India
Performance
Geographical Segment: Latin America
Performance
Geographical Segment: Rest of the World (ROW)
Performance
Geographical Segment: USA
Performance
R&D Overview
Glenmark Pharmaceuticals Ltd – Corporate Strategy
Glenmark Pharmaceuticals Ltd – SWOT Analysis
SWOT Analysis – Overview
Glenmark Pharmaceuticals Ltd – Strengths
Glenmark Pharmaceuticals Ltd – Weaknesses
Glenmark Pharmaceuticals Ltd – Opportunities
Glenmark Pharmaceuticals Ltd – Threats
Glenmark Pharmaceuticals Ltd – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Glenmark Pharmaceuticals Ltd, Recent Deals Summary
Section 5 – Company’s Recent Developments
Nov 14, 2019: Glenmark’s consolidated revenue rises 9.05% to Rs. 28,150.4 Mn. in Q2 FY 2019-20
Oct 05, 2019: Glenmark Pharmaceuticals: Update on the US FDA inspection of Glenmark’s Baddi manufacturing facility in Himachal Pradesh
Oct 03, 2019: US FDA issues warning letter to Glenmark Pharmaceuticals
Aug 13, 2019: Glenmark’s consolidated revenue atRs.23,228.79 Mn.for Q1 FY 2019–20
May 07, 2019: Glenmark appoints Dr. Yasir Rawjee as chief executive officer of Glenmark Life Sciences, its subsidiary for the API business
Mar 28, 2019: Glenmark: Intimation of Appointment of Ms. Sona Saira Ramasastry as an Additional Director – independent Director
Mar 06, 2019: Glenmark Pharmaceuticals appoints Alessandro Riva as CEO of its new innovation company
Feb 15, 2019: Glenmark Pharmaceuticals to establish new company in US
Feb 14, 2019: Glenmark’s consolidated revenue rises 15.95% to Rs. 25,550.45 Mn. in Q3 FY 2018 – 19
Dec 19, 2018: Glenmark Pharmaceuticals announces entry into branded dermatology segment in the United States
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Glenmark Pharmaceuticals Ltd, Key Facts
Glenmark Pharmaceuticals Ltd, Key Employees
Glenmark Pharmaceuticals Ltd, Key Employee Biographies
Glenmark Pharmaceuticals Ltd, Major Products and Services
Glenmark Pharmaceuticals Ltd, History
Glenmark Pharmaceuticals Ltd, Other Locations
Glenmark Pharmaceuticals Ltd, Subsidiaries
Glenmark Pharmaceuticals Ltd, Key Competitors
Glenmark Pharmaceuticals Ltd, Ratios based on current share price
Glenmark Pharmaceuticals Ltd, Annual Ratios
Glenmark Pharmaceuticals Ltd, Annual Ratios (Cont...1)
Glenmark Pharmaceuticals Ltd, Annual Ratios (Cont...2)
Glenmark Pharmaceuticals Ltd, Interim Ratios
Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2013 to YTD 2019
Glenmark Pharmaceuticals Ltd, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
Glenmark Pharmaceuticals Ltd, Performance Chart (2015 - 2019)
Glenmark Pharmaceuticals Ltd, Ratio Charts
Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2013 to YTD 2019
Glenmark Pharmaceuticals Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2013 to YTD 2019

★海外企業調査レポート[Glenmark Pharmaceuticals Ltd (GLENMARK):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • High Peak Royalties Ltd (HPR):電力:M&Aディール及び事業提携情報
    Summary High Peak Royalties Limited (High Peak) is a leading utility company that builds a portfolio of diversified resource royalties with projects in exploration, pre-production and producing phases. It assesses a regular flow of potential royalty investments across the resources sector. The compa …
  • Cytokinetics Inc (CYTK)-製薬・医療分野:企業M&A・提携分析
    Summary Cytokinetics Inc (Cytokinetics) is a late stage biopharmaceutical company, which discovers, develops, and commercializes muscle activators for the treatment of diseases, which compromise muscle performance. The company’s lead drug candidate, tirasemtiv, a fast skeletal muscle troponin activa …
  • NovoCure Ltd (NVCR):医療機器:M&Aディール及び事業提携情報
    Summary NovoCure Ltd (NovoCure) is an drug company that offers development and commercialization of novel therapies for tumor treating fields. The company’s pipeline products find application in cancer indications such as malignant melanoma, hepatocellular carcinoma, ovarian cancer, breast cancer an …
  • BRF SA:企業のM&A・事業提携・投資動向
    BRF SA - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's BRF SA Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital rais …
  • Axis Bank Limited:企業の戦略・SWOT・財務情報
    Axis Bank Limited - Strategy, SWOT and Corporate Finance Report Summary Axis Bank Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Medical Prognosis Institute A/S (MPI):企業の財務・戦略的SWOT分析
    Summary Medical Prognosis Institute A/S (MPI) is a precision medicine provider that offers cancer treatment solutions. The company offers drug response prediction platforms that provide tools for rationalized drug development and personalized medicine. It offers lead compound selection, drug rescue …
  • Magnitogorsk Metallurgicheskiy Kombinat:企業の戦略・SWOT・財務情報
    Magnitogorsk Metallurgicheskiy Kombinat - Strategy, SWOT and Corporate Finance Report Summary Magnitogorsk Metallurgicheskiy Kombinat - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT a …
  • Taageer Finance Company SAOG (TFCI):企業の財務・戦略的SWOT分析
    Taageer Finance Company SAOG (TFCI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • UCL Business PLC-医療機器分野:企業M&A・提携分析
    Summary UCL Business PLC (UCLB), a subsidiary of University College London is a technology transfer company that supports and markets research and innovations. The company offers licensing technologies and innovations, creates shared risk joint venture businesses, and promotes and supports the trans …
  • Japan Oil, Gas and Metals National Corp:企業の戦略的SWOT分析
    Japan Oil, Gas and Metals National Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and m …
  • Waste Management, Inc. (WM)-エネルギー分野:企業M&A・提携分析
    Summary Waste Management, Inc. (Waste Management) is a provider of comprehensive waste management environmental services. It provides services such as collection, transfer, recycling and resource recovery, and disposal. The company also develops, operates and owns landfill gas-to-energy facilities i …
  • Castle Brands Inc.:企業の戦略・SWOT・財務情報
    Castle Brands Inc. - Strategy, SWOT and Corporate Finance Report Summary Castle Brands Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Lonza Group Ltd (LONN):企業の財務・戦略的SWOT分析
    Lonza Group Ltd (LONN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • PGNiG SA (PGN):石油・ガス:M&Aディール及び事業提携情報
    Summary PGNiG SA (PGNiG) is a vertically integrated gas company. The company’s activities include domestic natural gas and crude oil production, development of natural gas and crude oil fields in Poland and abroad, provision of geological, geophysical and exploration services in Poland and abroad, i …
  • Nippon Suisan Kaisha, Ltd.:企業の戦略・SWOT・財務分析
    Nippon Suisan Kaisha, Ltd. - Strategy, SWOT and Corporate Finance Report Summary Nippon Suisan Kaisha, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Office Depot, Inc.:戦略・SWOT・企業財務分析
    Office Depot, Inc. - Strategy, SWOT and Corporate Finance Report Summary Office Depot, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Thai Airways International Public Co Ltd:企業の戦略・SWOT・財務分析
    Thai Airways International Public Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Thai Airways International Public Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • Nippon Soda Co., Ltd.:企業の戦略・SWOT・財務情報
    Nippon Soda Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Nippon Soda Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Laboratorio Reig Jofre SA-製薬・医療分野:企業M&A・提携分析
    Summary Laboratorio Reig Jofre SA (Reig Jofre) is a drug company that develops and manufactures medicinal products and nutritional supplements. The company’s product categories include specialized technology products, specialty therapeutic areas, and nutritional supplements and consumer healthcare. …
  • bet-at-home.com AG (ACX):企業の財務・戦略的SWOT分析
    bet-at-home.com AG (ACX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆